Jubilant Pharmova Limited today announced that the United States Food and Drug Administration (USFDA) has concluded audit of the Radiopharmaceutical manufacturing facility on April, 23, 2024 at Montreal, Canada of Jubilant Draximage, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited.
Zydus Lifesciences has received approval from WHO International Non-proprietary Names (INN) for “Usnoflast” as the recommended name for ZYIL1. The INN system aims to provide healthcare professionals with a unique and universal designated name for each pharma substance.
Jubilant Pharmova's wholly owned subsidiary Jubilant Pharma, today announced that its subsidiary Jubilant Generics (JGL) received a communication from the USFDA through which the regulatory agency intimated that pursuant to its January 25 to February 2, 2024 audit of JGL's Solid dosage manufacturing facility at Roorkee
Jubilant Generics` Roorkee site completes USFDA audit
Jubilant Pharmova Ltd on Tuesday announced leadership changes and board composition with Priyavrat Bhartia being appointed as Managing Director with incumbent Co-Chairman & Managing Director Hari S Bhartia deciding to step down as as part of its succession planning strategy. Priyavrat Bhartia, son of Chairman Shyam S Bhartia, will take over as Managing Director effective June 1, 2023. He has been a non-executive director since May 2017
Jubilant Pharmova Limited announced that the United States Food and Drug Administration (USFDA) has concluded inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility at Nanjangud on December 13, 2022. The US FDA has issued eight observations pursuant to the completion of the inspection. The company will submit an action plan on the observations and will engage with US FDA for next steps.
Jubilant Pharmova`s API unit at Nanjangud completes USFDA inspection
Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Pharma Limited, has announced that its subsidiary Jubilant Generics Limited (JGL) has received a communication from the USFDA through which the latter intimated that pursuant to its July-Aug 2022 audit of JGL’s Solid Dosage Manufacturing facility at Roorkee it has determined inspection classification of the facility as “official action indicated”.
Jubilant Pharmova announced that its wholly owned subsidiary, Jubilant Pharma, Singapore has on 18 August 2022 redeemed the principal amount of US$200,000,000 6% Senior Notes Due in 2024 at a redemption price of 103% together with the accrued interest.
New Delhi: Jubilant Pharma Holdings on Wednesday said it has signed an agreement with Standard Chartered Bank for a five-year loan of USD 400 million, about Rs 3,186 crore. The majority of the amount will be used for repayment of existing term loan and debt bonds, the company said in a regulatory filing.